Leukemia, Acute
21
2
4
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.5%
2 terminated out of 21 trials
81.8%
-4.7% vs benchmark
5%
1 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (21)
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
The SMART CART Study: Health Information Technology
The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia
Clinical Characteristics of Patients With Leukemia and COVID-19
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL